The RAD-VACCINE phase 2 trial aimed to provide an update on neoadjuvant sasanlimab and SBRT as an in-situ vaccine for MIBC. The primary objectives are safety, feasibility, and pCR. The trial is ongoing. Raj Satkunasivam and the team conducted a study that aimed to assess the safety and efficacy of combining neoadjuvant immunotherapy […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Background Natural killer (NK) cell therapy is considered an attractive and safe strategy for anticancer therapy. Nevertheless, when autologous or allogenic NK cells are used alone, the clinical benefit has been disappointing. This is partially due …
Background Lenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be further explored. We aimed to …
Background Triple-negative breast cancer (TNBC) poses unique challenges due to its complex nature and the need for more effective treatments. Recent studies showed encouraging outcomes from combining paclitaxel (PTX) with programmed cell death protein-1 (PD-1) blockade …
Background Cervical cancer’s lymphatic spread primarily begins from the sentinel lymph nodes (SLNs), underlining their pivotal role in disease metastasis. However, these nodes’ immune gene expression profiles and immunoregulation mechanisms have yet to be explored. Methods Our study …
